Browse

Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy

DC Field Value Language
dc.contributor.authorLee, Kyung-Hun-
dc.contributor.authorIm, Seock-Ah-
dc.contributor.authorOh, Do-Youn-
dc.contributor.authorLee, Se-Hoon-
dc.contributor.authorChie, Eui Kyu-
dc.contributor.authorHan, Wonshik-
dc.contributor.authorKim, Dong-Wan-
dc.contributor.authorKim, Tae-You-
dc.contributor.authorPark, In Ae-
dc.contributor.authorNoh, Dong-Young-
dc.contributor.authorHeo, Dae Seog-
dc.contributor.authorHa, Sung Whan-
dc.contributor.authorBang, Yung-Jue-
dc.date.accessioned2009-09-22T13:19:34Z-
dc.date.available2009-09-22T13:19:34Z-
dc.date.issued2007-04-
dc.identifier.citationBMC Cancer, Vol.7, p. 63-
dc.identifier.issn1471-2407-
dc.identifier.other95291-
dc.identifier.urihttps://hdl.handle.net/10371/9683-
dc.description.abstractBackground: Bcl-2 is positively regulated by hormonal receptor pathways in breast cancer. A study was conducted to assess the prognostic significances of clinico-pathologic variables and of ER, PR, p53, c-erbB2, bcl-2, or Ki-67 as markers of relapse in breast cancer patients who had received the identical adjuvant therapy at a single institution. Methods: A cohort of 151 curatively resected stage III breast cancer patients ( M: F = 3: 148, median age 46 years) who had 4 or more positive lymph nodes and received doxorubicin and cyclophosphamide followed by paclitaxel (AC/T) as adjuvant chemotherapy was analyzed for clinico-pathologic characteristics including disease-free survival (DFS) and overall survival ( OS). Patients with positive ER and/or PR expression received 5 years of tamoxifen following AC/T. The protein expressions of biomarkers were assessed immunohistochemically. Results: The median follow-up duration was 36 months, and 37 patients (24.5%) experienced a recurrence. Univariate analyses indicated that the tumor size ( P = 0.038) and the number of involved lymph nodes ( P < 0.001) significantly affected the recurrences. However, the type of surgery, the histology, histologic grade, the presence of endolymphatic emboli, and a close resection margin did not. Moreover, ER positivity ( P = 0.013), bcl-2 positivity ( P = 0.002) and low p53 expression ( P = 0.032) were found to be significantly associated with a prolonged DFS. Furthermore, multivariate analysis identified 10 or more involved lymph nodes (HR 7.366; P < 0.001), negative bcl-2 expression ( HR 2.895; P = 0.030), and c-erbB2 over-expression ( HR 3.535; P = 0.001) as independent indicators of poorer DFS. In addition, bcl-2 expression was found to be significantly correlated with the expressions of ER and PR, and inversely correlated with the expressions of p53, c-erbB2 and Ki-67. Patients with bcl-2 expression had a significantly longer DFS than those without, even in the ER (+) subgroup. Moreover, OS was significantly affected by ER, bcl-2 and c-erbB2. Conclusion: Bcl-2 is an independent prognostic factor of DFS in curatively resected stage III breast cancer patients and appears to be a useful prognostic factor in combination with c-erbB2 and the number of involved lymph nodes.-
dc.description.sponsorshipThis study was supported by a Korean Research Foundation Grant funded by
the Korean Government (MOEHRD, Basic Research Promotion Fund) (KRF-
2006-531-E00034) and by a grant from the Korean Health 21 R&D Project,
Ministry of Heath & Welfare, Republic of Korea (0412-CR01-0704-0001).
We also thank Julian Kanfer, English editor of BioMed Proofreading for her
assistance.
en
dc.language.isoenen
dc.publisherBioMed Centralen
dc.titlePrognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy-
dc.typeArticle-
dc.contributor.AlternativeAuthor방영주-
dc.identifier.doi10.1186/1471-2407-7-63-
dc.citation.journaltitleBMC Cancer-
dc.identifier.scopusid2-s2.0-34248177270-
dc.citation.startpage63-
dc.citation.volume7-
dc.identifier.urlhttps://bmccancer.biomedcentral.com/articles/10.1186/1471-2407-7-63-
dc.identifier.rimsid95291-
dc.identifier.sci000246354900001-
dc.description.isOpenAccessY-
dc.contributor.affiliatedAuthorKim, Dong-Wan-
dc.contributor.affiliatedAuthorBang, Yung-Jue-
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Internal Medicine (내과학전공)Journal Papers (저널논문_내과학전공)
Files in This Item:
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse